Ionis Price To Operating Cash Flows Ratio from 2010 to 2024
| IONS Stock | USD 39.87 0.18 0.45% |
Price To Operating Cash Flows Ratio | First Reported 2010-12-31 | Previous Quarter (23.56) | Current Value (22.38) | Quarterly Volatility 326.49558477 |
Check Ionis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ionis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.6 M, Interest Expense of 79.4 M or Total Revenue of 827 M, as well as many indicators such as Price To Sales Ratio of 15.6, Dividend Yield of 0.0 or PTB Ratio of 17.8. Ionis financial statements analysis is a perfect complement when working with Ionis Pharmaceuticals Valuation or Volatility modules.
Ionis | Price To Operating Cash Flows Ratio |
Latest Ionis Pharmaceuticals' Price To Operating Cash Flows Ratio Growth Pattern
Below is the plot of the Price To Operating Cash Flows Ratio of Ionis Pharmaceuticals over the last few years. It is Ionis Pharmaceuticals' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ionis Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Price To Operating Cash Flows Ratio | 10 Years Trend |
|
Price To Operating Cash Flows Ratio |
| Timeline |
Ionis Price To Operating Cash Flows Ratio Regression Statistics
| Arithmetic Mean | 156.54 | |
| Geometric Mean | 65.04 | |
| Coefficient Of Variation | 208.57 | |
| Mean Deviation | 221.24 | |
| Median | 24.46 | |
| Standard Deviation | 326.50 | |
| Sample Variance | 106,599 | |
| Range | 1.3K | |
| R-Value | (0.27) | |
| Mean Square Error | 106,160 | |
| R-Squared | 0.08 | |
| Significance | 0.32 | |
| Slope | (20.03) | |
| Total Sum of Squares | 1.5M |
Ionis Price To Operating Cash Flows Ratio History
About Ionis Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Ionis Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Ionis Pharmaceuticals investors use historical funamental indicators, such as Ionis Pharmaceuticals's Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although Ionis Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Ionis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Ionis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Ionis Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Ionis Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Operating Cash Flows Ratio | (23.56) | (22.38) |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.